Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.58 |
| ▸ | HPGD | P15428 | 7/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.58 |
| ▸ | CA9 | Q16790 | 6/20 | 0.58 |
| ▸ | GLA | P06280 | 6/20 | 0.58 |
| ▸ | GAA | P10253 | 6/20 | 0.58 |
| ▸ | CA12 | O43570 | 5/20 | 0.58 |
| ▸ | CASP1 | P29466 | 3/20 | 0.58 |
| ▸ | CASP7 | P55210 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359577 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL13881700 | 0.83 | CA9 (0.58) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL15842584 | 0.81 | PGR (0.43) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL27886627 | 0.80 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL724134 | 0.77 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL28401034 | 0.77 | RAB9A (0.51) | ALDH1A1KDM4EHPGDHSD17B10GLA | |
| SCHEMBL11886589 | 0.76 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL548396 | 0.76 | IDO1 (0.45) | ALDH1A1KDM4EHSD17B10CA9CA12 | |
| SCHEMBL30424058 | 0.75 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Hydrochloric Acid SCHEMBL30117164 | 0.75 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDHSD17B10CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-02 | — | — | US | disclosed |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE | 2022-06-30 | — | — | US | disclosed |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE | 2022-06-30 | — | — | US | disclosed |
| CN-114127050-A | Benzopyran and imidazole derivatives useful for stabilizing amyloidogenic immunoglobulin light chains | 斯克利普斯研究所 | 2022-03-01 | — | — | CN | disclosed |
| EP-3946604-A1 | BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | The Scripps Research Institute (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020205683-A1 | BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-10-08 | — | — | WO | disclosed |
| US-8283340-B2 | Treatment or prophylaxis of proliferative conditions | The University of the University of Dundee (GB) | 2012-10-09 | — | — | US | disclosed |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-07-26 | — | — | US | disclosed |
| US-8067619-B2 | Coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-29 | — | — | US | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JAIN NARESHKUMAR F | 2010-03-18 | — | — | US | disclosed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | disclosed |
| CN-101142203-A | Novel coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-12 | — | — | CN | disclosed |
| EP-1846386-A2 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | disclosed |
| WO-2006078833-A2 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | BRCA1, CYP1B1, UGT1A1 | ALDH1A1 35/4885KDM4E 4346/4885HPGD 132/4885 |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | TTR, MAP1LC3B, SAAL1 | ALDH1A1 2072/4885KDM4E 4575/4885HPGD 3113/4885 |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | KCNJ2, KCNN3, KCNN2 | ALDH1A1 1678/4885KDM4E 3289/4885HPGD 2449/4885 |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | ALDH1A1 55/4885KDM4E 3646/4885HPGD 143/4885 |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | KCNN2, KCNH3, KCNN1 | ALDH1A1 1703/4885KDM4E 756/4885HPGD 1322/4885 |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | TTR, MAP1LC3B, SAAL1 | ALDH1A1 2072/4885KDM4E 4575/4885HPGD 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.